Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)

Next Previous
Trial Profile

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemigatinib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms FIGHT-202
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 20 Mar 2023 According to Innovent media release, company announced that clinical data from this study will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando from 14th-19th April 2023. (Abstract No. CT030)
    • 15 Sep 2022 According to a Specialised Therapeutics Australia media release, PEMAZYRE (pemigatinib) has been provisionally approved by the Therapeutic Goods Administration (TGA) for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least one prior line of systemic therapy, based on data from this trial.
    • 23 Jul 2022 Results of Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing, published in the British Journal of Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top